Tenofovir Af + Emtricitabine Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Tenofovir AF 25 mg + Emtricitabine 200 mg
Reference Brands: Descovy(EU & US)
Category:
Anti Viral
Tenofovir Alafenamide (TAF) + Emtricitabine, sold as Descovy, is a once-daily HIV-1 treatment and PrEP option. It offers strong viral suppression with improved kidney and bone safety compared to TDF-based regimens. FDA and EMA approved.
Tenofovir AF + Emtricitabine is available in Tablet
and strengths such as Tenofovir AF 25 mg + Emtricitabine 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tenofovir AF + Emtricitabine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tenofovir AF + Emtricitabine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tenofovir Alafenamide (TAF) + Emtricitabine is a modern, once-daily antiretroviral combination used for the treatment and prevention of HIV-1 infection. Marketed under the brand name Descovy, this formulation offers a safer alternative to TDF-based regimens, with improved renal and bone safety. TAF is a prodrug of tenofovir, delivering effective viral suppression at a lower dose. Combined with Emtricitabine, an NRTI, it forms the backbone of several HIV therapies like Biktarvy, Genvoya, and Odefsey. Approved by the FDA and EMA, TAF + Emtricitabine is also used in PrEP to reduce the risk of HIV transmission in high-risk populations.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing